Mercado cerrado
Kyverna Therapeutics/KYTX
13:30
15:10
16:45
18:25
20:00
1D1S1MAHF1A5Y
Acerca de Kyverna Therapeutics
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
Símbolo
KYTX
Sector
Cotiza en
Industria
Biotecnología
Sede central
Empleados
100
Página web
Métricas de KYTX
BásicoAvanzado
346 M$
Capitalización
-
PER
-11,90 $
BPA
-
Beta
-
Dividendos
Precio y volumen
Capitalización
346 M$
Solvencia financiera
Ratio de solvencia
17,173
Test ácido
16,913
Ratio de endeudamiento a largo plazo
1,975
Ratio de endeudamiento total
3,005
Cobertura de intereses (TTM)
-423,63 %
Eficacia de la gestión
Valoración
Ratio precio-valor contable
0,96
Ratio precio-valor contable neto (TTM)
0,96
Ratio precio-flujo de caja libre (TTM)
-0,758
Crecimiento
Qué piensan los analistas de KYTX
Valoración de los Analistas
Calificaciones de analistas (comprar, conservar, vender) para la acción Kyverna Therapeutics.
Rendimiento financiero de KYTX
Cuenta de resultados
Ingresos y gastos
TrimestralAnual
Q3 24
Crecimiento intertrimestral
Ingresos
37 mil M$
-39,75 %
Beneficios
45 mil M$
107,52 %
Margen de beneficio
37,65 %
6,78 %
Rentabilidad de KYTX
Beneficios por acción (BPA)
Rentabilidad de la empresa
TrimestralAnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Real
3,69 $
2,85 $
2,45 $
2,42 $
-
Previsto
3,55 $
2,61 $
2,05 $
2,31 $
3,94 $
Sorpresa
3,94 %
9,20 %
19,51 %
4,63 %
-
Noticias de KYTX
TodosArtículosVídeos
![Kyverna Therapeutics Inc. Is Being Looked Into For Committing Securities Law Infractions And Stakeholders Are Invited To Help The Schall Law Firm](/_next/image?url=https%3A%2F%2Fcdn.snapi.dev%2Fimages%2Fv1%2Fb%2F3%2Fpress4-2619463.jpg&w=3840&q=75)
Kyverna Therapeutics Inc. Is Being Looked Into For Committing Securities Law Infractions And Stakeholders Are Invited To Help The Schall Law Firm
Accesswire·hace 14 horas
![A Securities Fraud Inquiry Has Been Launched Into Kyverna Therapeutics Inc And The Schall Law Firm Is Seeking Investor Participation](/_next/image?url=https%3A%2F%2Fcdn.snapi.dev%2Fimages%2Fv1%2Fy%2Ff%2Fpress11-2618177.jpg&w=3840&q=75)
A Securities Fraud Inquiry Has Been Launched Into Kyverna Therapeutics Inc And The Schall Law Firm Is Seeking Investor Participation
Accesswire·hace 2 días
![The Schall Law Firm Is Investigating Whether Kyverna Therapeutics Inc. Violated Securities Laws And Shareholders Are Urged To Reach Out](/_next/image?url=https%3A%2F%2Fcdn.snapi.dev%2Fimages%2Fv1%2F5%2Fn%2Fpress14-2616135.jpg&w=3840&q=75)
The Schall Law Firm Is Investigating Whether Kyverna Therapeutics Inc. Violated Securities Laws And Shareholders Are Urged To Reach Out
Accesswire·hace 3 días
Los datos expuestos son meramente indicativos y no se garantiza que sean exactos o completos. El precio de ejecución real puede variar. Rentabilidades pasadas no son indicativas de resultados futuros. Tu rentabilidad puede verse afectada por las fluctuaciones monetarias y las comisiones y gastos aplicables. Capital en riesgo.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.